LUC00117I2 - - Google Patents

Download PDF

Info

Publication number
LUC00117I2
LUC00117I2 LU00117C LUC00117C LUC00117I2 LU C00117 I2 LUC00117 I2 LU C00117I2 LU 00117 C LU00117 C LU 00117C LU C00117 C LUC00117 C LU C00117C LU C00117 I2 LUC00117 I2 LU C00117I2
Authority
LU
Luxembourg
Application number
LU00117C
Original Assignee
Oasmia Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40795732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00117(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oasmia Pharmaceutical Ab filed Critical Oasmia Pharmaceutical Ab
Publication of LUC00117I2 publication Critical patent/LUC00117I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU00117C 2007-12-19 2019-05-03 LUC00117I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE2007/001127 WO2009078754A1 (fr) 2007-12-19 2007-12-19 Système d'administration de médicament permettant d'administrer des substances pharmaceutiquement actives faiblement hydrosolubles

Publications (1)

Publication Number Publication Date
LUC00117I2 true LUC00117I2 (fr) 2024-05-22

Family

ID=40795732

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00117C LUC00117I2 (fr) 2007-12-19 2019-05-03

Country Status (27)

Country Link
US (4) US8999382B2 (fr)
EP (1) EP2231189B1 (fr)
JP (1) JP5466172B2 (fr)
KR (1) KR101572703B1 (fr)
CN (1) CN101951956B (fr)
AU (1) AU2008339099B2 (fr)
BR (1) BRPI0821740B1 (fr)
CA (1) CA2709266C (fr)
CY (2) CY1119805T1 (fr)
DK (1) DK2231189T3 (fr)
EA (1) EA015247B1 (fr)
ES (1) ES2650242T3 (fr)
FR (1) FR19C1030I1 (fr)
HR (1) HRP20171796T1 (fr)
HU (1) HUE034684T2 (fr)
LT (2) LT2231189T (fr)
LU (1) LUC00117I2 (fr)
MX (1) MX2010006914A (fr)
MY (2) MY157186A (fr)
NL (1) NL300987I9 (fr)
NO (2) NO2231189T3 (fr)
NZ (1) NZ586859A (fr)
PL (1) PL2231189T3 (fr)
PT (1) PT2231189T (fr)
SI (1) SI2231189T1 (fr)
WO (2) WO2009078754A1 (fr)
ZA (1) ZA201004685B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078755A1 (fr) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament pour administrer une substance pharmaceutiquement active amphiphile, cationique et hydrosoluble
WO2009078754A1 (fr) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament permettant d'administrer des substances pharmaceutiquement actives faiblement hydrosolubles
WO2009078756A1 (fr) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament pour administrer une substance pharmaceutiquement acceptable amphiphile, cationique et hydrosoluble
AU2010239689A1 (en) * 2009-04-21 2011-11-03 Selecta Biosciences, Inc. Immunonanotherapeutics providing a Th1-biased response
KR20130108983A (ko) 2010-05-26 2013-10-07 셀렉타 바이오사이언시즈, 인크. 커플링되지 않은 애주번트를 갖는 나노담체 조성물
WO2012061717A1 (fr) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Composés nicotiniques modifiés et procédés associés
CN103908432B (zh) * 2013-01-02 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种伊沙匹隆白蛋白的冻干组合物及其制备方法
CN112239418B (zh) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 视黄醇类化合物及其钠盐的制备方法
CN112321465B (zh) 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用
WO2021259472A1 (fr) * 2020-06-24 2021-12-30 Oasmia Pharmaceutical Ab Docétaxel micellaire à utiliser dans le traitement du cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
SE0202311D0 (sv) * 2002-07-23 2002-07-23 Ardenia Investments Ltd Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
WO2004009538A1 (fr) * 2002-07-23 2004-01-29 Ardenia Investments Ltd. Derives de retinol, leur utilisation dans le traitement du cancer et la potentialisation de l'efficacite d'autres agents cytotoxiques
US7259984B2 (en) * 2002-11-26 2007-08-21 Cornell Research Foundation, Inc. Multibit metal nanocrystal memories and fabrication
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005089106A2 (fr) 2004-02-27 2005-09-29 Molecular Therapeutics, Inc. Nanoparticules degradables
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
WO2007001356A2 (fr) * 2004-09-10 2007-01-04 University Of Wyoming Nanoparticules pour une distribution medicamenteuse cytoplasmique a des cellules cancereuses
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
WO2009078754A1 (fr) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament permettant d'administrer des substances pharmaceutiquement actives faiblement hydrosolubles
WO2009078756A1 (fr) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament pour administrer une substance pharmaceutiquement acceptable amphiphile, cationique et hydrosoluble
WO2009078755A1 (fr) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament pour administrer une substance pharmaceutiquement active amphiphile, cationique et hydrosoluble

Also Published As

Publication number Publication date
MX2010006914A (es) 2010-11-10
US8999382B2 (en) 2015-04-07
KR101572703B1 (ko) 2015-11-27
NZ586859A (en) 2012-06-29
EA015247B1 (ru) 2011-06-30
CN101951956A (zh) 2011-01-19
EA200802350A2 (ru) 2009-06-30
BRPI0821740A2 (pt) 2020-02-27
AU2008339099B2 (en) 2015-08-13
CA2709266A1 (fr) 2009-06-25
LTPA2019508I1 (lt) 2019-05-10
CY2019021I2 (el) 2019-11-27
HUE034684T2 (en) 2018-02-28
NO2231189T3 (fr) 2018-02-03
SI2231189T1 (en) 2018-03-30
AU2008339099A1 (en) 2009-06-25
HRP20171796T1 (hr) 2018-01-26
EP2231189B1 (fr) 2017-09-06
CN101951956B (zh) 2012-10-17
FR19C1030I1 (fr) 2019-06-21
BRPI0821740B1 (pt) 2021-05-18
MY157187A (en) 2016-05-13
DK2231189T3 (en) 2017-12-11
PT2231189T (pt) 2017-12-12
USRE49742E1 (en) 2023-12-05
KR20100094575A (ko) 2010-08-26
EP2231189A4 (fr) 2013-10-09
PL2231189T3 (pl) 2018-03-30
WO2009078802A1 (fr) 2009-06-25
MY157186A (en) 2016-05-13
CY2019021I1 (el) 2019-11-27
CA2709266C (fr) 2017-09-26
CY1119805T1 (el) 2018-06-27
NL300987I9 (nl) 2019-05-16
JP5466172B2 (ja) 2014-04-09
NL300987I2 (fr) 2019-05-09
EP2231189A1 (fr) 2010-09-29
WO2009078754A1 (fr) 2009-06-25
JP2011507838A (ja) 2011-03-10
US9993438B2 (en) 2018-06-12
NO2019023I1 (no) 2019-05-08
ZA201004685B (en) 2011-03-30
US20110014281A1 (en) 2011-01-20
ES2650242T3 (es) 2018-01-17
USRE49741E1 (en) 2023-12-05
EA200802350A3 (ru) 2009-10-30
LT2231189T (lt) 2017-12-27
US20150164819A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
LUC00117I2 (fr)
CN300728430S (zh) Led投光灯(方型lve-f240-24rgb)
CN300802271S (zh) 布料(77)
CN300895528S (zh) 糖果包装纸(大白莺)
CN300891682S (zh) 空气除臭装置
CN300856389S (zh) 管件接头(b205)
CN300728369S (zh) 电筒(节能强光防爆 jw7210)
CN300815175S (zh) 包装盒(香皂十)
CN300808932S (zh) 汽油锤(prh52)
CN300805372S (zh) 面料(4)
CN300728269S (zh) 静脉输液托盘(一)
CN300792835S (zh) 包装袋(一路发上汤排骨面)
CN300755948S (zh) 毛巾(2007-29)
CN300730175S (zh) 旋涡自吸泵(awzb)
CN300730150S (zh) 发动机护罩
CN300730134S (zh) 电路板(电流电压输入端子板)
CN300730029S (zh) Mp4播放器(660)
CN300729959S (zh) 用于安装束线的固定器
CN300729883S (zh) 金属轮毂(552)
CN300729881S (zh) 金属轮毂(370)
CN300729865S (zh) 仪表(汽车用六)
CN300729709S (zh) 首饰链(hy-an0004)
CN300729704S (zh) 首饰链(hy-an0035)
CN300729639S (zh) 电子手表(mp4-s808型)
CN300729616S (zh) 瓶盖(q28-410)